Subscribe
shutterstock_1144555808_piotr_swat
Piotr Swat / Shutterstock.com
10 October 2019AsiaRory O'Neill

Insilico Medicine signs $200m AI drug discovery deal

Hong Kong-based Insilico Medicine has agreed an artificial intelligence (AI) breast cancer drug discovery partnership worth a potential $200 million with a Chinese pharmaceutical company.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
EU invests €35m into AI cancer diagnostics
10 July 2019   The European Commission has pledged €35 million to promote the development of analysis of health images for cancer diagnostics, based on artificial intelligence.
Big Pharma
Novartis and BenevolentAI sign AI oncology deal
9 September 2019   Swiss pharmaceutical company Novartis has united with BenevolentAI to aid in the discovery and development of new treatments.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Big Pharma
EU invests €35m into AI cancer diagnostics
10 July 2019   The European Commission has pledged €35 million to promote the development of analysis of health images for cancer diagnostics, based on artificial intelligence.
Big Pharma
Novartis and BenevolentAI sign AI oncology deal
9 September 2019   Swiss pharmaceutical company Novartis has united with BenevolentAI to aid in the discovery and development of new treatments.

More on this story

Big Pharma
EU invests €35m into AI cancer diagnostics
10 July 2019   The European Commission has pledged €35 million to promote the development of analysis of health images for cancer diagnostics, based on artificial intelligence.
Big Pharma
Novartis and BenevolentAI sign AI oncology deal
9 September 2019   Swiss pharmaceutical company Novartis has united with BenevolentAI to aid in the discovery and development of new treatments.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Attorney v examiner: Navigating patenting's AI tools ‘arms race’
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool